Stifel lowered the firm’s price target on Disc Medicine (IRON) to $110 from $125 and keeps a Buy rating on the shares. The firm is updating its model to reflect FDA’s “surprise” issuance of a CRL for the bitopertin NDA seeking an accelerated approval for the treatment of EPP/XLP, notes the analyst, whose updated estimates now reflect mid-FY27 bitopertin commercialization with the trajectory of uptake and U.S. peak sales estimate of about $1B remaining largely-unchanged.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine price target lowered to $100 from $120 at BMO Capital
- Disc Medicine Addresses FDA Rejection of Bitopertin Filing
- Disc Medicine: Long‑Term Value Intact as Bitopertin Shifts to Lower‑Risk Traditional Approval Path
- Disc Medicine move down Friday ‘fair’ after bitopertin CRL, says Wells Fargo
- Disc Medicine Receives FDA Complete Response on Bitopertin